E

    Editas Medicine Inc (EDIT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.06
    -0.10 (-3.16%)

    Market Cap: $485.31M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(23/40)
    Avg Surprise
    -29.19%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.21
    Range$-0.25 - $-0.19
    7 analysts
    EPS Revisions
    5
    0
    7d
    5
    0
    30d
    EPS Estimate Drift
    90d ago$-0.27-31.7%
    60d ago$-0.28-35.3%
    30d ago$-0.28-35.3%
    7d ago$-0.28-35.9%
    Current$-0.21
    Revenue Consensus
    $4M
    Range$500000 - $12M
    11 analysts
    Dec 31, 2026
    EPS Consensus$-0.10
    Range$-0.26 - $0.07
    7 analysts
    Revenue Consensus
    $13M
    Range$4M - $26M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.10---
    Sep 26EST
    		-$-0.21---
    Jun 26
    		$-0.15$-0.30+50.00%Beat+53.1%
    Mar 26
    		$-0.26$-0.24-8.33%Miss+71.7%
    Dec 25
    		$-0.06N/A+73.94%Beat+89.1%
    Sep 25
    		$-0.28$-0.38+26.32%Beat+62.7%
    Jun 25
    		$-0.32$-0.38+15.79%Beat+61.0%
    Mar 25
    		$-0.92$-0.59-55.93%Miss-21.1%
    Dec 24
    		$-0.55$-0.33-67.38%Miss-139.1%
    Sep 24
    		$-0.75$-0.77+2.60%Beat-36.4%
    Jun 24
    		$-0.82$-0.71-15.49%Miss-46.4%
    Mar 24
    		$-0.76$-0.64-18.75%Miss-7.0%
    Dec 23
    		$-0.23N/A+57.41%Beat+73.9%
    Sep 23
    		$-0.55$-0.58+5.17%Beat+32.1%
    Jun 23
    		$-0.56$-0.77+27.27%Beat+28.2%
    Mar 23
    		$-0.71$-0.78+8.97%Beat+4.1%
    Dec 22
    		$-0.88$-0.81-8.64%Miss-44.3%
    Sep 22
    		$-0.81$-0.85+4.71%Beat-42.1%
    Jun 22
    		$-0.78$-0.80+2.50%Beat+3.7%
    Mar 22
    		$-0.74$-0.79+6.33%Beat+14.0%
    Dec 21
    		$-0.61$-0.72+15.28%Beat+39.0%
    Sep 21
    		$-0.57$-0.81+29.63%Beat-575.0%
    Jun 21
    		$-0.81$-0.81+0.00%Beat-88.4%
    Mar 21
    		$-0.86$-0.71-21.13%Miss-24.6%
    Dec 20
    		$-1.00$-0.74-35.14%Miss-35.1%
    Sep 20
    		$0.12N/A+119.05%Beat+118.2%
    Jun 20
    		$-0.43$-0.82+47.56%Beat+37.7%
    Mar 20
    		$-0.69$-0.79+12.66%Beat-15.0%
    Dec 19
    		$-0.74$0.06-1333.33%Miss-42.3%
    Sep 19
    		$-0.66$-0.73+9.59%Beat-106.3%
    Jun 19
    		$-0.69$-0.62-11.29%Miss+15.9%
    Mar 19
    		$-0.60$-0.64+6.25%Beat+10.4%
    Dec 18
    		$-0.52$-0.32-62.50%Miss+38.1%
    Sep 18
    		$-0.32N/A+60.49%Beat+50.0%
    Jun 18
    		$-0.82$-0.66-24.24%Miss-26.2%
    Mar 18
    		$-0.67$-0.80+16.25%Beat+21.2%
    Dec 17
    		$-0.84$-0.78-7.69%Miss+23.6%
    Sep 17
    		$-0.64$-0.63-1.59%Miss-8.5%
    Jun 17
    		$-0.65$-0.57-14.04%Miss-
    Mar 17
    		$-0.85$-0.77-10.39%Miss-
    Dec 16
    		$-1.10$-0.62-77.42%Miss-
    Sep 16
    		$-0.59$-0.64+7.81%Beat-

    Key Metrics

    Valuation
    P/E Ratio-4.08EV/EBITDA-1.36x
    Price/FCF-3.03xFCF Yield-33.02%
    Profitability
    Profit Margin-157.30%Operating Margin-167.30%
    ROE-118.80%ROIC-37.27%
    Financial Health
    Debt/Equity0.53xInterest Coverage-18.67x
    Current Ratio3.19xQuick Ratio3.19x
    Trading Statistics
    Beta2.06Avg Volume2.61M
    52-Week High$4.5452-Week Low$1.66

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.12
    SMA 20$2.98
    SMA 50$2.99
    SMA 200$2.60
    EMA 10$3.10
    EMA 20$3.02
    EMA 50$2.95
    EMA 200$2.73

    MACD

    Line: 0.08Signal: 0.05Hist: 0.03

    ADX

    ADX: 27.8+DI: 25.7-DI: 12.9

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down4.0
    PSAR$3.52

    Bollinger Bands

    Upper Band$3.33
    Lower Band$2.62
    %B Position2407%(Upper)
    Band Width0.62

    RSI (14-Day)

    Neutral
    52.0

    Momentum Oscillators

    Stoch %K57.3
    Stoch %D64.7
    Williams %R-56.9
    ROC (10d)7.7%
    Momentum0.22
    CCI (20d)35.2
    MFI (14d)56.0

    Volatility Measures

    ATR (14d)$0.23(7.4%)
    StdDev (20d)0.18
    Hist Vol83.5%(High)

    Volume Flow

    VWAP$3.07
    OBV71.8M
    AD Line-36.1M
    CMF (20d)-0.120

    Volume Metrics

    Avg Vol (20d)2.7M
    Vol Ratio0.8x
    VWMA (20d)$3.04

    Pivot Points

    R3$3.59
    R2$3.50
    R1$3.33
    Pivot Point$3.24
    S1$3.07
    S2$2.98
    S3$2.81

    Advanced Oscillators

    TSI9.93
    Ultimate Osc39.8
    KST61.44

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$11.89M$0$29.40M$7.54M$3.58M$0$-1,135,000$0$0$1.14M$60.05M$5.34M
    Cost of Revenue$0$0$805,000$0$0$0$48.61M$0$0$0$1.47M$0
    Gross Profit$11.89M$0$29.40M$7.54M$3.58M$0$-1,135,000$0$0$1.14M$60.05M$5.34M
    Operating Expenses$30.44M$25.00M$37.15M$32.09M$55.12M$76.16M$45.46M$65.67M$71.90M$68.13M$84.01M$55.50M
    R&D$20.18M$14.77M$32.06M$19.77M$16.18M$21.93M$16.87M$47.58M$53.70M$48.79M$69.56M$40.51M
    SG&A$11.60M$10.23M$11.35M$12.32M$12.86M$13.38M$16.35M$18.09M$18.21M$19.34M$14.46M$14.99M
    Operating Income$-18,554,000$-25,003,000$-7,755,000$-24,548,000$-51,544,000$-76,163,000$-46,592,000$-65,666,000$-71,903,000$-66,991,000$-23,963,000$-50,163,000
    Interest Income$1.37M$1.21M$1.68M$1.83M$2.09M$2.72M$3.39M$3.53M$4.30M$5.04M$5.10M$5.14M
    Interest Expense$1.06M$1.07M$-464,000$2.40M$2.02M$2.22M$2.19M$0$0$0$0$0
    Income Before Tax$-18,230,000$-24,982,000$-5,620,000$-25,117,000$-53,235,000$-76,088,000$-45,395,000$-62,141,000$-67,607,000$-61,950,000$-18,874,000$-45,019,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-18,230,000$-24,982,000$-5,620,000$-25,117,000$-53,235,000$-76,088,000$-45,395,000$-62,141,000$-67,607,000$-61,950,000$-18,874,000$-45,019,000
    EBITDA$-18,263,000$-24,633,000$-6,955,000$-23,890,000$-51,725,000$-75,254,000$-45,214,000$-65,398,000$-72,364,000$-67,292,000$-24,613,000$-49,896,000
    EBIT$-18,537,000$-25,116,000$-7,760,000$-24,549,000$-53,302,000$-76,588,000$-46,595,000$-65,671,000$-71,904,000$-66,985,000$-23,976,000$-50,163,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EDIT

    News

    Certain Stock Options of Editas Medicine, Inc. are subject to a Lock-Up Agreement Ending on 25-AUG-2026.

    Certain stock options for Editas Medicine, Inc. (EDIT) are subject to a lock-up agreement that ends on August 25, 2026. This lock-up period prevents executive officers and directors from selling or transferring beneficially owned shares or related securities for 90 days, starting from May 26, 2026. This measure is detailed in a prospectus supplement and aims to manage the market impact of new stock availability.

    www.marketscreener.com•8/25/26•
    Neutral

    ETFs Investing in Editas Medicine, Inc. Stocks

    This article provides a list of Exchange Traded Funds (ETFs) that hold Editas Medicine, Inc. stocks, sorted by market value. It details various ETFs, including those from BlackRock, Vanguard, and Invesco, highlighting their management style, focus, expense ratio, assets under management (AUM), and performance metrics. The information aims to help investors identify ETFs with exposure to Editas Medicine, Inc. for diversified investment opportunities.

    TradingView•8/20/26•
    Neutral

    Editas Medicine (NASDAQ:EDIT) Trading 14.4% Higher - Here's What Happened

    Editas Medicine (NASDAQ:EDIT) shares surged 14.4% to $3.30, with approximately 1.74 million shares traded. The company surpassed quarterly expectations, reporting an adjusted loss of $0.15 per share against an estimated $0.27 loss, and revenue of $11.89 million compared to a $2.85 million forecast. Analyst sentiment remains largely positive, holding a "Moderate Buy" consensus rating and an average price target of $5.50.

    MarketBeat•8/19/26•
    Bullish

    EDIT Initiates Coverage On Ladenburg Thalmann - Rating Set to Buy

    Ladenburg Thalmann has initiated coverage on Editas Medicine (EDIT) with a Buy rating and a price target of $6.00, according to GuruFocus. Despite this positive analyst outlook, GuruFocus indicates that EDIT is currently overvalued by 23.5% with a GF Value of $2.30 compared to its current price of $2.84, and has a moderate GF Score of 58/100 due to strong momentum but poor profitability. Investors are advised to proceed with caution given the high price-to-sales ratio and mixed insider activity.

    GuruFocus•8/18/26•
    Somewhat-Bullish

    Editas Medicine (NASDAQ:EDIT) Coverage Initiated at LADENBURG THALM/SH SH

    LADENBURG THALM/SH SH initiated coverage on Editas Medicine (NASDAQ:EDIT) with a "buy" rating and a $6.00 price target, representing a potential upside of over 111%. This follows Editas Medicine reporting quarterly revenue of $11.89 million and an adjusted loss of $0.15 per share, significantly exceeding analyst expectations. The company currently holds an average rating of "Moderate Buy" from analysts, with institutional investors owning a substantial 71.90% of the stock.

    MarketBeat•8/18/26•
    Bullish

    Frequently Asked Questions About EDIT

    Does EDIT pay dividends?
    Editas Medicine Inc (EDIT) does not currently pay a regular dividend.
    What is EDIT's market cap?
    Editas Medicine Inc (EDIT) has a market capitalization of $485.31M with a current stock price of $3.06.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In